Encompass Health Corp — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Encompass Health reported Q2 2026 revenue of $1,597.4M (+9.6% YoY) and Adjusted EBITDA of $348.0M (+9.2% YoY). The company raised full-year 2026 guidance: net operating revenue to $6,410–$6,490M (from $6,375–$6,470M), Adjusted EBITDA to $1,365–$1,395M (from $1,350–$1,380M), and adjusted EPS to $6.02–$6.25 (from $5.89–$6.11). On July 23, 2026, the board increased the common stock repurchase authorization to $1 billion; the company had repurchased 1,411,842 shares for $145.8M year-to-date and $188M remained under the prior authorization.
Why this rating
Solid operational results and modest guidance raise. At $12.2B market cap, $1B buyback authorization (~0.8% of market value) is material but not transformational. Company executing on capacity growth and shareholder returns.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.